Trials / Terminated
TerminatedNCT03835481
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
Phase II Long-term Extension Study to Assess the Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 730357 | Film-coated tablet |
| DRUG | Placebo to match BI 730357 | Film-coated tablet |
Timeline
- Start date
- 2019-03-18
- Primary completion
- 2021-06-22
- Completion
- 2021-07-27
- First posted
- 2019-02-08
- Last updated
- 2022-11-18
- Results posted
- 2022-11-18
Locations
30 sites across 3 countries: United States, Canada, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03835481. Inclusion in this directory is not an endorsement.